BG62973B1 - Имунореактивни полипептидни състави на вируса нахепатит с - Google Patents

Имунореактивни полипептидни състави на вируса нахепатит с Download PDF

Info

Publication number: BG62973B1
Authority: BG; Bulgaria
Prior art keywords: hcv; amino acid; sequences; variable domain; composition
Prior art date: 1991-09-13

Application number

BG98653A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG98653A (bg

Inventor

Amy Weiner

Michael Houghton

Original Assignee

Chiron Corporation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-09-13

Filing date

1994-03-11

Publication date

2000-12-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25056174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG62973(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1994-03-11 Application filed by Chiron Corporation filed Critical Chiron Corporation

1995-05-31 Publication of BG98653A publication Critical patent/BG98653A/bg

2000-12-29 Publication of BG62973B1 publication Critical patent/BG62973B1/bg

Links

239000000203 mixture Substances 0.000 title claims abstract description 102
108090000765 processed proteins & peptides Proteins 0.000 title claims description 161
102000004196 processed proteins & peptides Human genes 0.000 title claims description 132
229920001184 polypeptide Polymers 0.000 title claims description 105
241000700605 Viruses Species 0.000 title description 16
238000000034 method Methods 0.000 claims abstract description 56
150000001413 amino acids Chemical class 0.000 claims description 95
125000003275 alpha amino acid group Chemical group 0.000 claims description 60
101710158312 DNA-binding protein HU-beta Proteins 0.000 claims description 34
101710128560 Initiator protein NS1 Proteins 0.000 claims description 34
101710144127 Non-structural protein 1 Proteins 0.000 claims description 34
108020004414 DNA Proteins 0.000 claims description 20
241000711549 Hepacivirus C Species 0.000 claims description 18
239000000427 antigen Substances 0.000 claims description 18
108091007433 antigens Proteins 0.000 claims description 18
102000036639 antigens Human genes 0.000 claims description 18
230000002163 immunogen Effects 0.000 claims description 17
239000012472 biological sample Substances 0.000 claims description 15
230000000890 antigenic effect Effects 0.000 claims description 8
230000015572 biosynthetic process Effects 0.000 claims description 7
108010076039 Polyproteins Proteins 0.000 claims description 6
102000053602 DNA Human genes 0.000 claims description 5
101710185720 Putative ethidium bromide resistance protein Proteins 0.000 claims description 3
238000012258 culturing Methods 0.000 claims description 2
239000000945 filler Substances 0.000 claims 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 1
230000001939 inductive effect Effects 0.000 claims 1
230000003612 virological effect Effects 0.000 abstract description 24
238000002360 preparation method Methods 0.000 abstract description 16
239000000463 material Substances 0.000 abstract description 13
230000001900 immune effect Effects 0.000 abstract description 12
235000001014 amino acid Nutrition 0.000 description 92
108090000623 proteins and genes Proteins 0.000 description 61
210000004027 cell Anatomy 0.000 description 45
102000004169 proteins and genes Human genes 0.000 description 40
235000018102 proteins Nutrition 0.000 description 38
229960005486 vaccine Drugs 0.000 description 38
239000000243 solution Substances 0.000 description 28
210000002381 plasma Anatomy 0.000 description 25
239000013598 vector Substances 0.000 description 23
240000004808 Saccharomyces cerevisiae Species 0.000 description 22
108091033319 polynucleotide Proteins 0.000 description 22
102000040430 polynucleotide Human genes 0.000 description 22
239000002157 polynucleotide Substances 0.000 description 22
239000002299 complementary DNA Substances 0.000 description 19
108091032973 (ribonucleotides)n+m Proteins 0.000 description 18
230000027455 binding Effects 0.000 description 18
102000014914 Carrier Proteins Human genes 0.000 description 16
108010078791 Carrier Proteins Proteins 0.000 description 16
208000015181 infectious disease Diseases 0.000 description 15
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
210000004962 mammalian cell Anatomy 0.000 description 13
239000008363 phosphate buffer Substances 0.000 description 13
239000012634 fragment Substances 0.000 description 12
239000000523 sample Substances 0.000 description 12
238000012360 testing method Methods 0.000 description 12
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 11
238000006243 chemical reaction Methods 0.000 description 10
239000013604 expression vector Substances 0.000 description 10
239000002773 nucleotide Substances 0.000 description 10
125000003729 nucleotide group Chemical group 0.000 description 10
210000002966 serum Anatomy 0.000 description 10
108091026890 Coding region Proteins 0.000 description 9
230000004927 fusion Effects 0.000 description 9
238000002965 ELISA Methods 0.000 description 8
IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 8
239000000872 buffer Substances 0.000 description 8
208000006454 hepatitis Diseases 0.000 description 8
239000002245 particle Substances 0.000 description 8
239000000546 pharmaceutical excipient Substances 0.000 description 8
238000012546 transfer Methods 0.000 description 8
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
210000004369 blood Anatomy 0.000 description 7
239000008280 blood Substances 0.000 description 7
201000010099 disease Diseases 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
230000010076 replication Effects 0.000 description 7
230000028327 secretion Effects 0.000 description 7
238000003786 synthesis reaction Methods 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
241000713772 Human immunodeficiency virus 1 Species 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 6
241000282579 Pan Species 0.000 description 6
108010076504 Protein Sorting Signals Proteins 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
230000001684 chronic effect Effects 0.000 description 6
238000010367 cloning Methods 0.000 description 6
229960003983 diphtheria toxoid Drugs 0.000 description 6
-1 for example Chemical class 0.000 description 6
231100000283 hepatitis Toxicity 0.000 description 6
238000003018 immunoassay Methods 0.000 description 6
PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
230000004048 modification Effects 0.000 description 6
238000012986 modification Methods 0.000 description 6
230000003472 neutralizing effect Effects 0.000 description 6
229910052757 nitrogen Inorganic materials 0.000 description 6
238000012163 sequencing technique Methods 0.000 description 6
210000001519 tissue Anatomy 0.000 description 6
238000013519 translation Methods 0.000 description 6
101710118188 DNA-binding protein HU-alpha Proteins 0.000 description 5
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
241000710831 Flavivirus Species 0.000 description 5
241000238631 Hexapoda Species 0.000 description 5
102000014150 Interferons Human genes 0.000 description 5
108010050904 Interferons Proteins 0.000 description 5
101710144128 Non-structural protein 2 Proteins 0.000 description 5
101710144121 Non-structural protein 5 Proteins 0.000 description 5
101710199667 Nuclear export protein Proteins 0.000 description 5
229920001213 Polysorbate 20 Polymers 0.000 description 5
108010067390 Viral Proteins Proteins 0.000 description 5
239000002253 acid Substances 0.000 description 5
239000004480 active ingredient Substances 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
238000003556 assay Methods 0.000 description 5
239000003153 chemical reaction reagent Substances 0.000 description 5
235000018417 cysteine Nutrition 0.000 description 5
230000002068 genetic effect Effects 0.000 description 5
230000028993 immune response Effects 0.000 description 5
230000005847 immunogenicity Effects 0.000 description 5
239000007924 injection Substances 0.000 description 5
238000002347 injection Methods 0.000 description 5
229940079322 interferon Drugs 0.000 description 5
125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 5
OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 5
JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 5
229960005225 mifamurtide Drugs 0.000 description 5
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
230000009466 transformation Effects 0.000 description 5
241000894006 Bacteria Species 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
208000005176 Hepatitis C Diseases 0.000 description 4
108060003951 Immunoglobulin Proteins 0.000 description 4
241000282577 Pan troglodytes Species 0.000 description 4
241000710778 Pestivirus Species 0.000 description 4
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
241000288906 Primates Species 0.000 description 4
108010090804 Streptavidin Proteins 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
238000004422 calculation algorithm Methods 0.000 description 4
239000000969 carrier Substances 0.000 description 4
230000002860 competitive effect Effects 0.000 description 4
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000009472 formulation Methods 0.000 description 4
108020001507 fusion proteins Proteins 0.000 description 4
102000037865 fusion proteins Human genes 0.000 description 4
230000009851 immunogenic response Effects 0.000 description 4
102000018358 immunoglobulin Human genes 0.000 description 4
238000003780 insertion Methods 0.000 description 4
230000037431 insertion Effects 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
108020004999 messenger RNA Proteins 0.000 description 4
239000013612 plasmid Substances 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
230000001105 regulatory effect Effects 0.000 description 4
230000004044 response Effects 0.000 description 4
239000007787 solid Substances 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
238000013518 transcription Methods 0.000 description 4
230000035897 transcription Effects 0.000 description 4
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 3
KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 3
102000007698 Alcohol dehydrogenase Human genes 0.000 description 3
108010021809 Alcohol dehydrogenase Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241000725303 Human immunodeficiency virus Species 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
239000012901 Milli-Q water Substances 0.000 description 3
108091028043 Nucleic acid sequence Proteins 0.000 description 3
108700026244 Open Reading Frames Proteins 0.000 description 3
229920005654 Sephadex Polymers 0.000 description 3
239000012507 Sephadex™ Substances 0.000 description 3
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
102000019197 Superoxide Dismutase Human genes 0.000 description 3
108010012715 Superoxide dismutase Proteins 0.000 description 3
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 3
241000700618 Vaccinia virus Species 0.000 description 3
108020000999 Viral RNA Proteins 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
125000000539 amino acid group Chemical group 0.000 description 3
230000003321 amplification Effects 0.000 description 3
230000000692 anti-sense effect Effects 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
238000001574 biopsy Methods 0.000 description 3
229960002685 biotin Drugs 0.000 description 3
235000020958 biotin Nutrition 0.000 description 3
239000011616 biotin Substances 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
238000010276 construction Methods 0.000 description 3
238000001514 detection method Methods 0.000 description 3
238000006073 displacement reaction Methods 0.000 description 3
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
230000037406 food intake Effects 0.000 description 3
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000011534 incubation Methods 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
238000012317 liver biopsy Methods 0.000 description 3
244000005700 microbiome Species 0.000 description 3
238000003199 nucleic acid amplification method Methods 0.000 description 3
230000008520 organization Effects 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
229920000053 polysorbate 80 Polymers 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
230000009257 reactivity Effects 0.000 description 3
210000003705 ribosome Anatomy 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
239000012488 sample solution Substances 0.000 description 3
238000000926 separation method Methods 0.000 description 3
239000001632 sodium acetate Substances 0.000 description 3
235000017281 sodium acetate Nutrition 0.000 description 3
229940031439 squalene Drugs 0.000 description 3
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 3
239000000829 suppository Substances 0.000 description 3
125000003396 thiol group Chemical group [H]S* 0.000 description 3
238000001890 transfection Methods 0.000 description 3
241000701447 unidentified baculovirus Species 0.000 description 3
210000005253 yeast cell Anatomy 0.000 description 3
QMXCRMQIVATQMR-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-pyridin-2-ylsulfanylpropanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSC1=CC=CC=N1 QMXCRMQIVATQMR-UHFFFAOYSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
241000701822 Bovine papillomavirus Species 0.000 description 2
241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
241000283707 Capra Species 0.000 description 2
241000700198 Cavia Species 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
241000699800 Cricetinae Species 0.000 description 2
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
101150082674 E2 gene Proteins 0.000 description 2
108010067770 Endopeptidase K Proteins 0.000 description 2
241000710781 Flaviviridae Species 0.000 description 2
102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
108090000288 Glycoproteins Proteins 0.000 description 2
102000003886 Glycoproteins Human genes 0.000 description 2
102100034349 Integrase Human genes 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
241000282560 Macaca mulatta Species 0.000 description 2
241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
101150033828 NS1 gene Proteins 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
241001494479 Pecora Species 0.000 description 2
108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
241000714474 Rous sarcoma virus Species 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 2
108091081024 Start codon Proteins 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
241000251539 Vertebrata <Metazoa> Species 0.000 description 2
206010058874 Viraemia Diseases 0.000 description 2
DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
238000007792 addition Methods 0.000 description 2
NWMHDZMRVUOQGL-CZEIJOLGSA-N almurtide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)CO[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O NWMHDZMRVUOQGL-CZEIJOLGSA-N 0.000 description 2
108010050122 alpha 1-Antitrypsin Proteins 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
235000012538 ammonium bicarbonate Nutrition 0.000 description 2
239000001099 ammonium carbonate Substances 0.000 description 2
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
229960000723 ampicillin Drugs 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
230000002238 attenuated effect Effects 0.000 description 2
239000011324 bead Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
108010051210 beta-Fructofuranosidase Proteins 0.000 description 2
229960005069 calcium Drugs 0.000 description 2
239000011575 calcium Substances 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229960001714 calcium phosphate Drugs 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
239000002775 capsule Substances 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
239000006143 cell culture medium Substances 0.000 description 2
230000008859 change Effects 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
239000008367 deionised water Substances 0.000 description 2
229910021641 deionized water Inorganic materials 0.000 description 2
239000005547 deoxyribonucleotide Substances 0.000 description 2
125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
238000011161 development Methods 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
241001493065 dsRNA viruses Species 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
238000000605 extraction Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
230000002414 glycolytic effect Effects 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
230000002440 hepatic effect Effects 0.000 description 2
208000002672 hepatitis B Diseases 0.000 description 2
208000010710 hepatitis C virus infection Diseases 0.000 description 2
230000006801 homologous recombination Effects 0.000 description 2
238000002744 homologous recombination Methods 0.000 description 2
230000008348 humoral response Effects 0.000 description 2
230000000984 immunochemical effect Effects 0.000 description 2
229940072221 immunoglobulins Drugs 0.000 description 2
238000010324 immunological assay Methods 0.000 description 2
239000007972 injectable composition Substances 0.000 description 2
239000007928 intraperitoneal injection Substances 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000002502 liposome Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000013507 mapping Methods 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
150000002739 metals Chemical class 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
230000035772 mutation Effects 0.000 description 2
244000052769 pathogen Species 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
230000026731 phosphorylation Effects 0.000 description 2
238000006366 phosphorylation reaction Methods 0.000 description 2
230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
230000002265 prevention Effects 0.000 description 2
108020001580 protein domains Proteins 0.000 description 2
ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
238000003259 recombinant expression Methods 0.000 description 2
230000009467 reduction Effects 0.000 description 2
FGDZQCVHDSGLHJ-UHFFFAOYSA-M rubidium chloride Chemical compound [Cl-].[Rb+] FGDZQCVHDSGLHJ-UHFFFAOYSA-M 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229940074404 sodium succinate Drugs 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000008961 swelling Effects 0.000 description 2
229960000814 tetanus toxoid Drugs 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
230000032258 transport Effects 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
241000701161 unidentified adenovirus Species 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
238000002255 vaccination Methods 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
LQILVUYCDHSGEU-UHFFFAOYSA-N 4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexane-1-carboxylic acid Chemical compound C1CC(C(=O)O)CCC1CN1C(=O)C=CC1=O LQILVUYCDHSGEU-UHFFFAOYSA-N 0.000 description 1
WOJKKJKETHYEAC-UHFFFAOYSA-N 6-Maleimidocaproic acid Chemical compound OC(=O)CCCCCN1C(=O)C=CC1=O WOJKKJKETHYEAC-UHFFFAOYSA-N 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
102100034044 All-trans-retinol dehydrogenase [NAD(+)] ADH1B Human genes 0.000 description 1
101710193111 All-trans-retinol dehydrogenase [NAD(+)] ADH4 Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
101100163849 Arabidopsis thaliana ARS1 gene Proteins 0.000 description 1
108010002913 Asialoglycoproteins Proteins 0.000 description 1
241001367049 Autographa Species 0.000 description 1
238000012935 Averaging Methods 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
238000000035 BCA protein assay Methods 0.000 description 1
241000193830 Bacillus <bacterium> Species 0.000 description 1
102100026189 Beta-galactosidase Human genes 0.000 description 1
241000588832 Bordetella pertussis Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
102100033620 Calponin-1 Human genes 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
241000222128 Candida maltosa Species 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
102000011632 Caseins Human genes 0.000 description 1
108010076119 Caseins Proteins 0.000 description 1
108010039939 Cell Wall Skeleton Proteins 0.000 description 1
102100037633 Centrin-3 Human genes 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
241001227713 Chiron Species 0.000 description 1
241000282552 Chlorocebus aethiops Species 0.000 description 1
206010008631 Cholera Diseases 0.000 description 1
206010008909 Chronic Hepatitis Diseases 0.000 description 1
241000744472 Cinna Species 0.000 description 1
241000710777 Classical swine fever virus Species 0.000 description 1
101710094648 Coat protein Proteins 0.000 description 1
208000003322 Coinfection Diseases 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
208000001490 Dengue Diseases 0.000 description 1
206010012310 Dengue fever Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
108090000204 Dipeptidase 1 Proteins 0.000 description 1
101150029662 E1 gene Proteins 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
108010058643 Fungal Proteins Proteins 0.000 description 1
101150038242 GAL10 gene Proteins 0.000 description 1
102100024637 Galectin-10 Human genes 0.000 description 1
102100039556 Galectin-4 Human genes 0.000 description 1
108700007698 Genetic Terminator Regions Proteins 0.000 description 1
102000030595 Glucokinase Human genes 0.000 description 1
108010021582 Glucokinase Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
108700008783 Hepatitis C virus E1 Proteins 0.000 description 1
206010019791 Hepatitis post transfusion Diseases 0.000 description 1
102000005548 Hexokinase Human genes 0.000 description 1
108700040460 Hexokinases Proteins 0.000 description 1
101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 1
101000880522 Homo sapiens Centrin-3 Proteins 0.000 description 1
101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 1
101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 description 1
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
101000666657 Homo sapiens Rho-related GTP-binding protein RhoQ Proteins 0.000 description 1
101000652736 Homo sapiens Transgelin Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
241000235058 Komagataella pastoris Species 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
206010024264 Lethargy Diseases 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
108700015872 N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine Proteins 0.000 description 1
108700020354 N-acetylmuramyl-threonyl-isoglutamine Proteins 0.000 description 1
125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
101710141454 Nucleoprotein Proteins 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
241000282520 Papio Species 0.000 description 1
108010087702 Penicillinase Proteins 0.000 description 1
102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
241000235648 Pichia Species 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
108010020346 Polyglutamic Acid Proteins 0.000 description 1
108010039918 Polylysine Proteins 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
101710083689 Probable capsid protein Proteins 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
238000002123 RNA extraction Methods 0.000 description 1
239000013614 RNA sample Substances 0.000 description 1
230000004570 RNA-binding Effects 0.000 description 1
241000700159 Rattus Species 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
208000035415 Reinfection Diseases 0.000 description 1
102100038339 Rho-related GTP-binding protein RhoQ Human genes 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
241000702670 Rotavirus Species 0.000 description 1
WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
241000277331 Salmonidae Species 0.000 description 1
241000235347 Schizosaccharomyces pombe Species 0.000 description 1
101100097319 Schizosaccharomyces pombe (strain 972 / ATCC 24843) ala1 gene Proteins 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
241000282887 Suidae Species 0.000 description 1
206010042566 Superinfection Diseases 0.000 description 1
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
ODMZDQKUHYGKKN-UHFFFAOYSA-N TCA C Natural products CC(CCCC(C)C1=CCC2(C)OC3=C(CC12)C(=O)C(O)CC3)C(=O)O ODMZDQKUHYGKKN-UHFFFAOYSA-N 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
108010034949 Thyroglobulin Proteins 0.000 description 1
102000009843 Thyroglobulin Human genes 0.000 description 1
108700009124 Transcription Initiation Site Proteins 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
206010046865 Vaccinia virus infection Diseases 0.000 description 1
108010003533 Viral Envelope Proteins Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
241000235013 Yarrowia Species 0.000 description 1
208000003152 Yellow Fever Diseases 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000010310 bacterial transformation Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
102000006635 beta-lactamase Human genes 0.000 description 1
230000001588 bifunctional effect Effects 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
239000012490 blank solution Substances 0.000 description 1
239000010836 blood and blood product Substances 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
229940125691 blood product Drugs 0.000 description 1
KDPAWGWELVVRCH-UHFFFAOYSA-N bromoacetic acid Chemical compound OC(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-N 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
PPBOKXIGFIBOGK-BDTUAEFFSA-N bvdv Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)C(C)C)[C@@H](C)CC)C1=CN=CN1 PPBOKXIGFIBOGK-BDTUAEFFSA-N 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
229940095731 candida albicans Drugs 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
210000004520 cell wall skeleton Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
231100000749 chronicity Toxicity 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000004040 coloring Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000004590 computer program Methods 0.000 description 1
239000003636 conditioned culture medium Substances 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
238000012937 correction Methods 0.000 description 1
238000012864 cross contamination Methods 0.000 description 1
150000001945 cysteines Chemical class 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
208000025729 dengue disease Diseases 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
206010013023 diphtheria Diseases 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
238000001035 drying Methods 0.000 description 1
235000006694 eating habits Nutrition 0.000 description 1
229960001484 edetic acid Drugs 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000011888 foil Substances 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
230000036541 health Effects 0.000 description 1
229910001385 heavy metal Inorganic materials 0.000 description 1
108060003552 hemocyanin Proteins 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
102000055277 human IL2 Human genes 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
230000004957 immunoregulator effect Effects 0.000 description 1
229960001438 immunostimulant agent Drugs 0.000 description 1
239000003022 immunostimulating agent Substances 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
239000003999 initiator Substances 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
239000001573 invertase Substances 0.000 description 1
235000011073 invertase Nutrition 0.000 description 1
JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
230000003902 lesion Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
230000004807 localization Effects 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000003550 marker Substances 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
108700007621 mifamurtide Proteins 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
229940035032 monophosphoryl lipid a Drugs 0.000 description 1
125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
230000004942 nuclear accumulation Effects 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
210000003463 organelle Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
238000012856 packing Methods 0.000 description 1
208000014451 palmoplantar keratoderma and congenital alopecia 2 Diseases 0.000 description 1
239000013610 patient sample Substances 0.000 description 1
229950009506 penicillinase Drugs 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
230000002688 persistence Effects 0.000 description 1
239000000575 pesticide Substances 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
229920001515 polyalkylene glycol Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920002643 polyglutamic acid Polymers 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
108010045496 pro-corticotropin releasing hormone Proteins 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
230000008569 process Effects 0.000 description 1
XUWVIABDWDTJRZ-UHFFFAOYSA-N propan-2-ylazanide Chemical compound CC(C)[NH-] XUWVIABDWDTJRZ-UHFFFAOYSA-N 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
210000001938 protoplast Anatomy 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
VMXUWOKSQNHOCA-UKTHLTGXSA-N ranitidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-UKTHLTGXSA-N 0.000 description 1
239000000376 reactant Substances 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000003014 reinforcing effect Effects 0.000 description 1
238000004153 renaturation Methods 0.000 description 1
210000005000 reproductive tract Anatomy 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
229940102127 rubidium chloride Drugs 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000007789 sealing Methods 0.000 description 1
238000012882 sequential analysis Methods 0.000 description 1
230000011664 signaling Effects 0.000 description 1
235000020183 skimmed milk Nutrition 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229940080237 sodium caseinate Drugs 0.000 description 1
239000012064 sodium phosphate buffer Substances 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000012086 standard solution Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
108020001568 subdomains Proteins 0.000 description 1
239000000758 substrate Substances 0.000 description 1
229960002317 succinimide Drugs 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000003826 tablet Substances 0.000 description 1
210000001138 tear Anatomy 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
150000007970 thio esters Chemical class 0.000 description 1
150000003568 thioethers Chemical class 0.000 description 1
229960004906 thiomersal Drugs 0.000 description 1
229960002175 thyroglobulin Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
230000002463 transducing effect Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
208000007089 vaccinia Diseases 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
230000008299 viral mechanism Effects 0.000 description 1
210000002845 virion Anatomy 0.000 description 1
230000002747 voluntary effect Effects 0.000 description 1
239000002569 water oil cream Substances 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
208000016261 weight loss Diseases 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/82—Hepatitis associated antigens and antibodies
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/826—Viruses

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

BG98653A 1991-09-13 1994-03-11 Имунореактивни полипептидни състави на вируса нахепатит с BG62973B1 (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US75957591A	1991-09-13	1991-09-13
PCT/US1992/007683 WO1993006126A1 (en)	1991-09-13	1992-09-11	Immunoreactive hepatitis c virus polypeptide compositions

Publications (2)

Publication Number	Publication Date
BG98653A BG98653A (bg)	1995-05-31
BG62973B1 true BG62973B1 (bg)	2000-12-29

Family

ID=25056174

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG98653A BG62973B1 (bg)	1991-09-13	1994-03-11	Имунореактивни полипептидни състави на вируса нахепатит с

Country Status (16)

Country	Link
US (6)	US5756312A (de)
EP (1)	EP0608261B1 (de)
JP (5)	JPH06511149A (de)
AT (1)	ATE228564T1 (de)
AU (1)	AU679429B2 (de)
BG (1)	BG62973B1 (de)
CA (1)	CA2116764C (de)
DE (1)	DE69232859T2 (de)
DK (1)	DK0608261T3 (de)
ES (1)	ES2182822T3 (de)
FI (1)	FI112438B (de)
HU (1)	HU227510B1 (de)
PL (2)	PL171972B1 (de)
RO (1)	RO116199B1 (de)
RU (2)	RU2136311C1 (de)
WO (1)	WO1993006126A1 (de)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6596476B1 (en) *	1989-12-22	2003-07-22	Abbott Laboratories	Hepatitis C assay
WO1993006126A1 (en) *	1991-09-13	1993-04-01	Chiron Corporation	Immunoreactive hepatitis c virus polypeptide compositions
US6297048B1 (en) *	1992-02-04	2001-10-02	Chiron Corporation	Hepatitis therapeutics
US6667387B1 (en)	1996-09-30	2003-12-23	N.V. Innogenetics S.A.	HCV core peptides
US6709828B1 (en)	1992-03-06	2004-03-23	N.V. Innogenetics S.A.	Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
DE69332485T2 (de) *	1992-08-11	2003-11-13	The President And Fellows Of Harvard College, Cambridge	Immunmodulierende peptide
EP0651807B1 (de)	1993-04-27	2007-09-12	N.V. Innogenetics S.A.	Sequenzen der genotype des hepatitis-c-virus sowie ihre verwendung als arzneimitteln und diagnostika
US7255997B1 (en)	1993-04-27	2007-08-14	N.V. Innogenetics S.A.	Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents
JPH08510240A (ja)	1993-05-12	1996-10-29	カイロンコーポレイション	Ｃ型肝炎ウイルスｅ２／ｎｓ１領域の保存モチーフ
US5514539A (en) *	1993-06-29	1996-05-07	The United States Of America As Represented By The Department Of Health And Human Services	Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
EP0992580B1 (de)	1993-11-04	2005-03-09	Innogenetics N.V.	Von menschlichen T-Zellen immunodominante Epitopen des Virus der C-Hepatitis
CA2195753C (en)	1994-07-25	2008-12-16	Ursula-Henrike Wienhues	Determination of a specific immunoglobulin using multiple antigens
BR9506059A (pt) *	1994-07-29	1997-10-28	Innogenetics Nv	Proteinas envelopes purificadas de virus c para uso de diagnóstico e terapêutico
WO1996013590A2 (en) *	1994-10-21	1996-05-09	Innogenetics N.V.	New sequences of hepatitis c virus genotypes and their use as prophylactic, therapeutic and diagnostic agents
US6110465A (en) *	1995-06-07	2000-08-29	The United States Of America As Represented By The Department Of Health And Human Services	Nucleotide and deduced amino acid sequences of hypervariable region 1 of the envelope 2 gene of isolates of hepatitis C virus and the use of reagents derived from these hypervariable sequences in diagnostic methods and vaccines
US6127116A (en) *	1995-08-29	2000-10-03	Washington University	Functional DNA clone for hepatitis C virus (HCV) and uses thereof
US7235394B1 (en)	1995-08-29	2007-06-26	Washington University	Functional DNA clone for hepatitis C virus (HCV) and uses thereof
US7045363B2 (en) *	1996-05-01	2006-05-16	Fujirebio Inc.	Nucleic acid-bound polypeptide method of producing nucleic acid-bound polypeptide and immunoassay using the polypeptide
US6001613A (en) *	1996-05-24	1999-12-14	Board Of Regents Of University Of Nebraska	Plasmid bearing a cDNA copy of the genome of bovine viral diarrhea virus, chimeric derivatives thereof, and method of producing an infectious bovine viral diarrhea virus using said plasmid
CA2269097C (en)	1996-11-08	2007-01-09	The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Synthesis and purification of hepatitis c virus-like particles
US6322965B1 (en) *	1997-02-10	2001-11-27	Advanced Life Science Institute, Inc.	Chimera antigen peptide
US7049428B1 (en) *	1998-03-04	2006-05-23	Washington University	HCV variants
US7338759B1 (en)	1997-03-04	2008-03-04	Washington University	HCV variants
WO1999024466A2 (en) *	1997-11-06	1999-05-20	Innogenetics N.V.	Multi-mer peptides derived from hepatitis c virus envelope proteins for diagnostic use and vaccination purposes
US6683058B1 (en)	1998-04-15	2004-01-27	Regents Of The University Of California	Methods for therapy of neurodegenerative disease of the brain
US6451306B1 (en)	1998-04-15	2002-09-17	The Regents Of The University Of California	Methods for therapy of neurodegenerative disease of the brain
US6815431B2 (en)	1998-04-15	2004-11-09	Regents Of The University Of California	Methods for therapy of neurodegenerative disease of the brain
US7157435B2 (en)	1998-04-15	2007-01-02	The Regents Of The University Of California	Methods for modulation of the effects of aging on the primate brain
US7052830B1 (en) *	1998-06-09	2006-05-30	Branch Andrea D	Hepatitis C virus peptides and uses thereof
US7108855B2 (en) *	1998-06-24	2006-09-19	Innogenetics N.V.	Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US6548634B1 (en) *	1998-09-30	2003-04-15	Chiron Corporation	Synthetic peptides having FGF receptor affinity
US7091324B2 (en)	1998-11-05	2006-08-15	Board Of Trustees Of Leland Stanford Junior University	Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
US20030180284A1 (en) *	1998-11-05	2003-09-25	Board Of Trustees Of Leland Stanford Junior University	Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
US7935805B1 (en)	1998-12-31	2011-05-03	Novartis Vaccines & Diagnostics, Inc	Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
WO2000039302A2 (en)	1998-12-31	2000-07-06	Chiron Corporation	Improved expression of hiv polypeptides and production of virus-like particles
AU2487300A (en) *	1998-12-31	2000-07-31	Chiron Corporation	Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
ES2299276T3 (es) *	1998-12-31	2008-05-16	Novartis Vaccines And Diagnostics, Inc.	Polipeptidos env del vih modificados.
EP1535628B1 (de) *	1999-11-24	2013-07-31	Novartis Vaccines and Diagnostics, Inc.	Hbv/hcv virus-ähnliche teilchen
US6740323B1 (en)	1999-11-24	2004-05-25	Chiron Corporation	HBV/HCV virus-like particle
NZ524070A (en) *	2000-07-19	2008-05-30	Univ California	Methods for therapy of neurodegenerative disease of the non-human brain
US6680059B2 (en)	2000-08-29	2004-01-20	Tripep Ab	Vaccines containing ribavirin and methods of use thereof
JP5175417B2 (ja)	2000-08-17	2013-04-03	トリペップアクチボラゲット	リバビリンを含むワクチンおよびその使用方法
US7022830B2 (en)	2000-08-17	2006-04-04	Tripep Ab	Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
RU2286172C2 (ru)	2000-08-17	2006-10-27	Трипеп Аб	Вакцины, содержащие рибавирин, и способы их использования
AU2001292667A1 (en)	2000-09-13	2002-03-26	Hawaii Biotechnology Group, Inc.	Immunogenic composition of hepatitis c and methods of use thereof
RU2195668C2 (ru) *	2001-02-12	2002-12-27	Мешандин Алексей Гаврилович	Способ постановки реакции агглютинационного иммунологического анализа
CZ20033515A3 (cs) *	2001-06-29	2005-01-12	Chiron Corporation	Kompozice vakcíny HCV E1E2
EP2292772A1 (de)	2001-07-05	2011-03-09	Novartis Vaccines and Diagnostics, Inc.	HIV Impfung mit für ein HIV Polypeptid kodierender DNS und einem HIV Polypeptid
AU2002320314A1 (en)	2001-07-05	2003-01-21	Chiron, Corporation	Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) *	2001-08-31	2003-09-11	Megede Jan Zur	Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
CA2458995C (en) *	2001-08-31	2013-04-30	Chiron Corporation	Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
AR045702A1 (es) *	2001-10-03	2005-11-09	Chiron Corp	Composiciones de adyuvantes.
EP1587838B1 (de) *	2003-01-10	2015-04-15	Ablynx N.V.	Therapeutische polypeptide, deren homologe, deren fragmente und deren verwendung bei der modulierung der thrombozytenvermittelten aggregation
US20070073048A1 (en)	2003-05-15	2007-03-29	Ying Lian	Hiv polynucleotides and polypeptides derived from botswana mj4
WO2005010035A2 (en) *	2003-07-22	2005-02-03	Branch Andrea D	Alternate reading frame polypeptides derived from hepatitis c and methods of their use
US20050130131A1 (en) *	2003-08-14	2005-06-16	California Institute Of Molecular Medicine	Method for isolation and replication of infectious human hepatitis-C virus
ES2596753T3 (es)	2003-08-29	2017-01-11	Fujirebio Europe N.V.	Nuevo clado del virus de la hepatitis C y secuencias prototipo del mismo
WO2006050394A2 (en)	2004-11-01	2006-05-11	Novartis Vaccines And Diagnostics Inc.	Combination approaches for generating immune responses
CA2618429A1 (en) *	2005-05-25	2007-03-22	Tripep Ab	A hepatitis c virus non-structural ns3/4a fusion gene
GB0524066D0 (en) *	2005-11-25	2006-01-04	Chiron Srl	741 ii
EP1989326A4 (de)	2006-01-17	2009-09-30	Health Research Inc	Heteroduplex-verfolgungstest
EP2185195A2 (de) *	2007-08-16	2010-05-19	Tripep Ab	Immunogen-plattform
US20090214593A1 (en) *	2007-08-16	2009-08-27	Tripep Ab	Immunogen platform
US20100286070A1 (en) *	2007-09-14	2010-11-11	Gert Verheyden	Affinity tag
KR102069498B1 (ko)	2007-09-28	2020-01-23	포톨라 파마슈티컬스, 인코포레이티드	인자 Ｘａ 저해제에 대한 안티도트 및 그것을 사용하는 방법
US20100104555A1 (en) *	2008-10-24	2010-04-29	The Scripps Research Institute	HCV neutralizing epitopes
PL3604510T3 (pl)	2009-03-30	2025-07-28	Alexion Pharmaceuticals, Inc.	Antidota na inhibitory czynnika xa i sposoby ich stosowania
US20100322943A1 (en)	2009-06-17	2010-12-23	Thomas Cantor	Therapeutic and diagnostic affinity purified specific polyclonal antibodies
PT2453910T (pt)	2009-07-15	2016-12-07	Portola Pharm Inc	Formulação de dose unitária de antídoto contra inibidores de fator xa para uso na prevenção de sangramento
CA2840965C (en)	2011-07-06	2021-03-02	Novartis Ag	Cationic oil-in-water emulsions
SG10201605512WA (en)	2011-07-06	2016-09-29	Novartis Ag	Oil-in-water emulsions that contain nucleic acids
WO2013016449A2 (en)	2011-07-26	2013-01-31	Indicator Systems International, Inc.	Assays for the detection of microbes
FR2984328B1 (fr)	2011-12-20	2016-12-30	Bio-Rad Innovations	Procede de detection d'une infection par le virus de l'hepatite c
JP6200437B2 (ja)	2012-03-16	2017-09-20	ユニバーシティヘルスネットワーク	Ｔｏｓｏ活性を調節するための方法および組成物
RU2520710C1 (ru) *	2012-12-10	2014-06-27	Государственное бюджетное образовательное учреждение высшего профессионального образования "Челябинская государственная медицинская академия" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО ЧелГМА Минздравсоцразвития России)	Способ прогнозирования персистенции онкогенных типов вируса папилломы человека в цервикальном эпителии
EP3113798B1 (de)	2014-03-07	2019-06-05	University Health Network	Verfahren und zusammensetzungen zur modifikation der immunantwort
RU2675108C2 (ru) *	2015-06-15	2018-12-17	Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт биомедицинской химии имени В.Н. Ореховича" (ИБМХ)	Композиция на основе синтетических пептидов и липидов для вакцины против гепатита с
WO2017011275A1 (en)	2015-07-10	2017-01-19	Nersissian Aram M	Factor viii protein compositions and methods of treating hemophilia a
WO2017066719A2 (en)	2015-10-14	2017-04-20	Research Institute At Nationwide Children's Hospital	Hu specific interfering agents
AU2018206560B9 (en)	2017-01-04	2025-04-03	Research Institute At Nationwide Children's Hospital	Antibody fragments for the treatment of biofilm-related disorders
JP7514621B2 (ja)	2017-01-04	2024-07-11	リサーチインスティチュートアットネイションワイドチルドレンズホスピタル	Ｄｎａｂｉｉワクチンおよび強化された活性を有する抗体
AU2018236271B2 (en)	2017-03-15	2023-12-21	Research Institute At Nationwide Children's Hospital	Composition and methods for disruption of bacterial biofilms without accompanying inflammation
WO2021007260A2 (en)	2019-07-08	2021-01-14	Research Institute At Nationwide Children's Hospital	Antibody compositions for disrupting biofilms

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3400079A1 (de) *	1984-01-03	1985-07-11	Röhm GmbH, 6100 Darmstadt	Wasserspreitendes kunststoffmaterial, verfahren zu seiner herstellung u. verwendung als verglasungs- und bedachungsmaterial
US4673634A (en) *	1985-03-08	1987-06-16	The United States Of America As Represented By The Department Of Health And Human Services	Purified antigen from non-A, non-B hepatitis causing factor
JPS6391328A (ja) *	1986-10-07	1988-04-22	Mitsubishi Kasei Corp	非ａ非ｂ型肝炎抗原
NZ219516A (en) *	1987-02-10	1991-02-26	Wellcome Found	Fusion proteins of hbcag (hepatitis b virus core antigen)
US5350671A (en) *	1987-11-18	1994-09-27	Chiron Corporation	HCV immunoassays employing C domain antigens
NZ227011A (en) *	1987-11-18	1992-03-26	Chiron Corp	Non-a, non-b-hepatitis (hepatitis c) antigens, proteins, nucleotide sequences, vaccines and kits
US5191064A (en) *	1988-09-30	1993-03-02	The Research Foundation For Microbial Diseases (Osaka University)	Non-a, non-b hepatitis virus antigen peptide
JPH02167081A (ja) *	1988-12-21	1990-06-27	Tetsuo Nakamura	非Ａ非Ｂ型肝炎ウイルスゲノムＲＮＡ、ｃＤＮＡおよびウイルス抗原蛋白質
KR0185373B1 (ko) *	1989-03-17	1999-05-01	로버트 피. 블랙버언	Hcv 폴리단백질에서 유래되는 hcv 아미노산 서열 부분을 포함하는 폴리펩티드 및 그 사용
DK0398748T3 (da) *	1989-05-18	2002-03-18	Chiron Corp	NANBV-diagnostika: polynukleotider anvendelige til screening for hepatitis C virus
US5372928A (en) *	1989-09-15	1994-12-13	Chiron Corporation	Hepatitis C virus isolates
WO1991004262A1 (en) *	1989-09-15	1991-04-04	National Institute Of Health Of Japan	New hcv isolates
ATE206717T1 (de) *	1990-11-03	2001-10-15	Dade Behring Marburg Gmbh	Hcv-spezifische peptide, mittel dazu und ihre verwendung
WO1993006126A1 (en) *	1991-09-13	1993-04-01	Chiron Corporation	Immunoreactive hepatitis c virus polypeptide compositions

1992
- 1992-09-11 WO PCT/US1992/007683 patent/WO1993006126A1/en not_active Ceased
- 1992-09-11 PL PL92313797A patent/PL171972B1/pl unknown
- 1992-09-11 PL PL92302729A patent/PL171489B1/pl unknown
- 1992-09-11 RU RU94024561A patent/RU2136311C1/ru active
- 1992-09-11 AU AU26436/92A patent/AU679429B2/en not_active Expired
- 1992-09-11 RU RU98117084/14A patent/RU2212899C2/ru active
- 1992-09-11 DE DE69232859T patent/DE69232859T2/de not_active Expired - Lifetime
- 1992-09-11 ES ES92919917T patent/ES2182822T3/es not_active Expired - Lifetime
- 1992-09-11 CA CA002116764A patent/CA2116764C/en not_active Expired - Lifetime
- 1992-09-11 JP JP5506119A patent/JPH06511149A/ja not_active Withdrawn
- 1992-09-11 RO RO94-00391A patent/RO116199B1/ro unknown
- 1992-09-11 HU HU9400741A patent/HU227510B1/hu unknown
- 1992-09-11 AT AT92919917T patent/ATE228564T1/de active
- 1992-09-11 EP EP92919917A patent/EP0608261B1/de not_active Expired - Lifetime
- 1992-09-11 DK DK92919917T patent/DK0608261T3/da active
1994
- 1994-03-11 BG BG98653A patent/BG62973B1/bg unknown
- 1994-03-14 FI FI941199A patent/FI112438B/fi not_active IP Right Cessation
- 1994-04-19 US US08/231,368 patent/US5756312A/en not_active Expired - Lifetime
1995
- 1995-05-12 US US08/440,542 patent/US5670153A/en not_active Expired - Lifetime
- 1995-05-12 US US08/440,210 patent/US5766845A/en not_active Expired - Lifetime
- 1995-05-12 US US08/440,103 patent/US5670152A/en not_active Expired - Lifetime
- 1995-06-06 US US08/471,498 patent/US5728520A/en not_active Expired - Lifetime
1998
- 1998-03-24 US US09/046,604 patent/US6303292B1/en not_active Expired - Fee Related
2001
- 2001-07-11 JP JP2001211447A patent/JP2002167336A/ja not_active Withdrawn
2003
- 2003-09-18 JP JP2003326811A patent/JP2004073207A/ja not_active Withdrawn
2005
- 2005-01-27 JP JP2005020454A patent/JP4353905B2/ja not_active Expired - Lifetime
2008
- 2008-02-20 JP JP2008038799A patent/JP2008133301A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
DK0608261T3 (da)	2003-03-17
CA2116764C (en)	1999-12-07
HUT67342A (en)	1995-03-28
US5728520A (en)	1998-03-17
JP2005176853A (ja)	2005-07-07
FI941199A0 (fi)	1994-03-14
US5670153A (en)	1997-09-23
JP2004073207A (ja)	2004-03-11
RU2212899C2 (ru)	2003-09-27
EP0608261A4 (de)	1995-03-15
EP0608261A1 (de)	1994-08-03
CA2116764A1 (en)	1993-04-01
RO116199B1 (ro)	2000-11-30
PL171489B1 (pl)	1997-05-30
ES2182822T3 (es)	2003-03-16
JP2008133301A (ja)	2008-06-12
US6303292B1 (en)	2001-10-16
FI941199L (fi)	1994-04-27
BG98653A (bg)	1995-05-31
DE69232859T2 (de)	2003-04-10
EP0608261B1 (de)	2002-11-27
WO1993006126A1 (en)	1993-04-01
PL171972B1 (pl)	1997-07-31
DE69232859D1 (de)	2003-01-16
FI112438B (fi)	2003-12-15
ATE228564T1 (de)	2002-12-15
HU9400741D0 (en)	1994-06-28
JP4353905B2 (ja)	2009-10-28
US5756312A (en)	1998-05-26
US5766845A (en)	1998-06-16
US5670152A (en)	1997-09-23
AU2643692A (en)	1993-04-27
RU2136311C1 (ru)	1999-09-10
JPH06511149A (ja)	1994-12-15
JP2002167336A (ja)	2002-06-11
HU227510B1 (en)	2011-07-28
AU679429B2 (en)	1997-07-03

Publication	Publication Date	Title
BG62973B1 (bg)	2000-12-29	Имунореактивни полипептидни състави на вируса нахепатит с
JP2662358B2 (ja)	1997-10-08	Ｎａｎｂｖの診断用薬
JP2656995B2 (ja)	1997-09-24	Ｎａｎｂｖの診断用薬
EP0419182A1 (de)	1991-03-27	HCV-Isolate
US5766840A (en)	1998-06-16	Hepatitis G virus and molecular cloning thereof
BG61843B1 (bg)	1998-07-31	Полипептиди на вируса на хепатит с (нсv)
US7252827B1 (en)	2007-08-07	Conserved motif of hepatitis C virus E2/NS1 region
US5874563A (en)	1999-02-23	Hepatitis G virus and molecular cloning thereof
AU684177B2 (en)	1997-12-04	Hepatitis G virus and molecular cloning thereof
MXPA97009271A (en)	1999-01-11	Diagnosis of, and vaccination against, in positive thread rna virus using an isolated polypeptide, do not process